When loved ones are critically ill, what are families willing to pay to keep them on a path to improved health? In 2015, Turing Pharmaceuticals found itself in the middle of a controversial issue when it purchased an existing drug-Daraprim-from another pharmaceutical company. Daraprim has been around for 62 years and is used to treat life-threatening parasitic infections in AIDS and cancer patients. After acquiring Daraprim, Turing Pharmaceuticals CEO Martin Shkreli quickly raised its price from the previous $13.50 per pill to a whopping $750 per pill. According to CNN Money, CEO Shkreli stated, "We needed to turn a profit on this drug." He added the company would use the profits to research better ways to treat diseases.
Research the Daraprim pricing issue. Is it wrong for Turing Pharmaceuticals to charge such a high price for this medication? Support your position.